Molecular Partners AG (MOLN) shares rose on the Swiss companys trading debut, the second-biggest biotechnology offering in Europe since 2007, as Allergan (AGN) Inc. supported the sale.

Molecular Partners put its listing on hold two weeks ago, citing a volatile stock market, and resumed book-building for the offer two days ago. Allergan, the Irvine, California-based drugmaker that funds development of Molecular Partners most advanced eye medicine, supported the IPO with an investment, according to the Swiss company.

U.S. investors are increasingly recognizing the attractiveness of European biotech, said Samir Devani, a health-care analyst at Rx Securities.

The stock rose 4.2 percent from the 22.40-franc offer price in Zurich today, after surging as much as 12 percent. Molecular Partners sold almost 23 percent of its shares, raising about 100 million Swiss francs ($104 million), not counting an over-allotment option, according to data compiled by Bloomberg.

Investors filter for quality, so maybe the quantity of IPOs is to decline, but the window for companies with proximity to revenues is not closed yet, Navid Malik, a London-based analyst at Cenkos Securities Plc, said by phone.

Christian Zahn, Molecular Partners chief executive officer, declined to disclose Allergans stake in an interview two days ago and said the company is not seeking a takeover.

Another possible Swiss IPO candidate may be biotechnology company NovImmune SA, newspaper Finanz und Wirtschaft reported. The company hired Andrew Oakley, former chief financial officer of Actelion (ATLN) Ltd., in March as its CFO.

To contact the reporter on this story: Jan-Henrik Frster in Zurich at jforster20@bloomberg.net

To contact the editors responsible for this story: Mariajose Vera at mvera1@bloomberg.net James Kraus

Press spacebar to pause and continue. Press esc to stop.

Go here to read the rest:

Molecular Partners Up in Trading Debut on Allergan Support